Current status of intravenous iron therapy
| Beneficial (reference) . | No benefit (reference) . | Investigational (reference) . |
|---|---|---|
| Anemia of renal failure, with or without erythropoietin therapy52-54 Patients with ongoing blood loss35 51 Jehovah's Witness patients with iron deficiency,50 blood loss,51 or both | Autologous blood donation in patients with or without iron deficiency12 13 | Blood loss, iron deficiency, and erythropoietin therapy27,32 Anemia of chronic disease and erythropoietin therapy29,31,55 Perisurgical anemia, with or without erythropoietin therapy28 35 |
| Beneficial (reference) . | No benefit (reference) . | Investigational (reference) . |
|---|---|---|
| Anemia of renal failure, with or without erythropoietin therapy52-54 Patients with ongoing blood loss35 51 Jehovah's Witness patients with iron deficiency,50 blood loss,51 or both | Autologous blood donation in patients with or without iron deficiency12 13 | Blood loss, iron deficiency, and erythropoietin therapy27,32 Anemia of chronic disease and erythropoietin therapy29,31,55 Perisurgical anemia, with or without erythropoietin therapy28 35 |
Absolute iron deficiency is defined as ferritin <200 μg/L with or without iron saturation <20%, or relative iron deficiency (ferritin <400 μg/L in dialysis patients receiving erythropoietin therapy54 or the presence of >10% hypochromic erythrocytes, reticulocytes, or both.